Serum MG53 as a diagnostic marker for tissue injury
View Patent ↗Disclosed herein are compositions and methods for measuring the level of MG53 found in a biological fluid as a biomarker for a disease or disorder, e.g., tissue damage, exercise capacity or a muscle-related disease or disorder. In addition, the invention relates to targeting the native MG53 found in the blood as a therapeutic approach.
1. A method for diagnosing and/or monitoring at least one of a muscle tissue injury, exercise capacity, muscle-related disease or disorder or combination thereof in a subject comprising the steps of:
a) isolating or obtaining from at least one time point, a biological fluid sample selected from the group consisting of whole blood, plasma, serum, and a combination thereof, from a subject to be tested (“test sample”);
b) determining the presence and/or amount of MG53 in the test sample;
c) comparing the presence and/or amount of MG53 in the test sample to a reference or control sample; and
d) identifying whether the subject has at least one of a muscle tissue injury, a change in exercise capacity, a muscle-related disease or disorder or a combination thereof.
2. The method of claim 1 , wherein an increase in the presence and/or amount of MG53 relative to a reference or control sample is indicative of at least one of muscle tissue injury, exercise capacity or a muscle-related disease or disorder.
3. The method of claim 1 , wherein a decrease in the presence and/or amount of MG53 relative to a reference or control sample is indicative of at least one of muscle tissue injury, exercise capacity or a muscle-related disease or disorder.
4. The method of claim 1 , wherein prior to step (c) a step is performed comprising isolating or obtaining a biological fluid sample selected from the group consisting of whole blood, plasma, serum, and a combination thereof, from a reference or control subject (“reference sample”).
5. The method of claim 4 , wherein the reference or control subject is the same or different from the test subject.
6. The method of claim 1 , wherein test sample is taking from two or more time points.
7. The method of claim 1 , further comprising a step after (d) of initiating or modifying a therapeutic or exercise regimen.
8. The method of claim 1 , wherein the biological fluid sample is whole blood.
9. The method of claim 1 , wherein the biological fluid sample is serum.
10. The method of claim 1 , wherein the muscle tissue injury is at least one of exercise related, age-related muscle degeneration, ischemic reperfusion injury, trauma induced injury to skeletal or cardiac muscle or a combination thereof.
11. The method of claim 1 , wherein the muscle tissue injury is ischemic reperfusion injury.
12. The method of claim 1 , wherein the muscle-related disease or disorder is muscular dystrophy.
13. The method of claim 1 , wherein the presence and/or amount of MG53 is determined using an anti-MG53 antibody.
14. The method of claim 1 , wherein the antibody binds immunospecifically to a polypeptide having an amino acid sequence of at least one of SEQ ID NO. 1, 3, or 5-13.
15. The method of claim 13 , wherein the presence and/or amount of MG53 is determined by assaying the sample with an immunoassay.
16. The method of claim 15 , wherein said immunoassay is an enzyme-linked immunosorbent assay (ELISA).
17. The method of claim 13 , wherein the presence and/or amount of MG53 is determined by assaying the sample with an immunohistochemical assay.
18. The method of claim 17 , wherein said immunohistochemical assay is an immunofluorescence assay.
19. A method for determining whether treatment with a therapeutic agent should be continued in a subject suffering from a muscle tissue injury or a muscle-related disease or disorder comprising the steps of:
a) isolating or obtaining from at least two time points during the course of treatment, a biological fluid sample selected from the group consisting of whole blood, plasma, serum, and a combination thereof, from a subject to be tested (“test samples”);
b) determining the presence and/or amount of MG53 in the test samples;
c) comparing the presence and/or amount of MG53 in the test samples; and
d) continuing the treatment when the presence and/or amount of MG53 does not increase or is decreased during the course of treatment or discontinuing the treatment when presence and/or amount of MG53 is increased during the course of treatment.
20. A method for screening agents or combinations of agents for treating muscle tissue injury or a muscle-related disease or disorder comprising the steps of:
a) obtaining a biological fluid sample selected from the group consisting of whole blood, plasma, serum, and a combination thereof, from a subject to be tested (“test sample”), wherein the subject has received treatment with an agent or combination of agents;
b) determining whether the test sample contains MG53;
c) comparing the test sample to a reference or control sample from the same or a different subject; and
c) identifying that the agent is or is not appropriate to treat the disease or disorder based on the presence and/or amount of MG53 in the test sample, wherein an agent is identified as being appropriate to treat or ameliorate a disease or disorder when the presence and/or amount of MG53 in the test sample is decreased.